O
ATRC icon

OrbiMed’s AtriCure ATRC Stock Holding History

OrbiMed’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,228,189
Closed -$68.4M – 163
2020
Q4 		$68.4M Hold
1,228,189
– – 0.6% 47
2020
Q3 		$49M Hold
1,228,189
– – 0.62% 50
2020
Q2 		$55.2M Buy
1,228,189
+300,000
+32% +$13.1M 0.78% 40
2020
Q1 		$31.2M Buy
928,189
+759,568
+450% +$27.3M 0.52% 51
2019
Q4 		$5.48M Buy
+168,621
New +$4.8M 0.08% 101

Other funds holding ATRC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed's ATRC Position: Q1 2021 in Review

OrbiMed sold out of AtriCure (ATRC) in Q1 2021, closing a stake of 1,228,189 shares — an estimated $68.4M sold.

OrbiMed first reported a position in ATRC in Q4 2019 and held it in 5 quarters. The position peaked at $68.4M in Q4 2020. 191 funds tracked by Wall St. Rank hold ATRC as of Q1 2021.

  • OrbiMed reported no remaining AtriCure position as of Q1 2021 after selling out during the quarter.
  • OrbiMed sold 1,228,189 AtriCure shares in Q1 2021, an estimated $68.4M.
  • OrbiMed first reported a position in AtriCure in Q4 2019 and held it in 5 quarters.
  • OrbiMed's AtriCure position peaked at $68.4M in Q4 2020.
  • 191 funds tracked by Wall St. Rank held AtriCure as of Q1 2021.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.